Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

Roche to acquire InterMune Inc. for $8.3 Billion


Roche and InterMune, Inc. announced they ...

FDA approves Triumeq triple therapy for HIV-1 Infection- Viiv HealthCare


ViiV Healthcare announced that the ...

FDA approves Eliquis for DVT and PE (VTE).- BMS + Pfizer


BMS and Pfizer Inc. announced the ...

Cubist Pharma files ceftolozane/tazobactam at EMA for Urinary Tract and Intra Abdominal Infections.


Cubist Pharmaceuticals, Inc. ...

BAX 855 success in Phase III trial for Haemophilia A prophylaxis- Baxter


Baxter International Inc. announced ...

FDA approves Arnuity Ellipta for treatment of Asthma- GSK


GlaxoSmithKline plc announced that ...

Eisai files Fycompa at EMA and FDA for uncontrolled primary generalized Tonic-Clonic Seizures.


Eisai has filed its anti-epileptic ...

Recent Updates


Clinical Guidelines

Drug misuse: opioid detoxification

Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease

Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients

ESC Guidelines on Myocardial Revascularization

Medical Journals

Excellent Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Acquired Severe Aplastic Anemia

A randomised trial of fluticasone furoate/vilanterol (50/25 ?g; 100/25 ?g) on lung function in COPD

Thigh circumference and low ankle brachial index in US adults: Results from the National Health and Nutrition Examination Survey 1999–2004

Biophysical measures of skin tissue water: variations within and among anatomical sites and correlations between measures

epgonline.org Social